Analyst coverage
Newron is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Newron’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions by Newron or its management. Newron does not by its reference below imply its endorsement of or concurrence with such opinion, conclusions or recommendations.
| FIRM | ANALYST |
|---|---|
| Baader Helvea | Leonildo Delgado |
| Valuation Lab | Bob Pooler |
| Rx Securities | Samir Devani |
| Edison Investment Research | Soo Romanoff /Harry Shrives |
According to the Italian law, certain transactions involving financial instruments issued by Italian resident companies are subject to Italian Financial Transaction Tax (IFTT).
There is an exemption for Italian resident companies whose average market capitalisation in the month of November of the year preceding the year of sale does not exceed €500 million.
A list of the Italian issuing companies having an average capitalization lower than EUR 500 million is accessible on MEF’s official website at https://www.mef.gov.it/pubblicita_legale/societa_2025.html
As Newron is included in the list (see sezione B); should you be charged by your bank the Italian financial transaction tax upon purchase or sale of Newron stock, please contact your bank
A constantly updated overview of Newron‘s major shareholders can be found on the website of the SIX Swiss Stock Exchange (Significant-shareholders list)
Newron:
Stefan Weber – CEO
Arianna Baldo – Assistant
Phone: +39 02 6103 46 26
E-mail: [email protected]
UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting
+44 20 3727 1000
[email protected]
Switzerland
Valentin Handschin, IRF Reputation AG
+41 43 244 81 54
[email protected]
Germany/Europe
Anne Hennecke/ Caroline Bergmann, MC Services
+49 211 52925222
[email protected]
USA
Paul Sagan, LaVoieHealthScience
+1 617 374 8800, Ext. 112
[email protected]